NCT06716567View on ClinicalTrials.gov

Maternal Determinants of Immunity to Influenza

PHASE4CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions
Vaccination; InfectionMaternal-Fetal RelationsInfluenzaImmunoglobulins
Interventions
BIOLOGICAL

Influenza vaccine

Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.

Trial Locations (1)

1000

CHU Saint-Pierre, Brussels

All Listed Sponsors
collaborator

Institute for Medical Immunology, Université libre de Bruxelles

UNKNOWN

lead

Centre Hospitalier Universitaire Saint Pierre

OTHER

NCT06716567 - Maternal Determinants of Immunity to Influenza | Biotech Hunter | Biotech Hunter